|
CVD Risk and Health in Postmenopausal Phytoestrogen Users Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on CVD Risk and Health in Postmenopausal Phytoestrogen Users conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. CVD Risk and Health in Postmenopausal Phytoestrogen Users Clinical research trials and CVD Risk and Health in Postmenopausal Phytoestrogen Users medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like CVD Risk and Health in Postmenopausal Phytoestrogen Users. CVD Risk and Health in Postmenopausal Phytoestrogen Users Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a CVD Risk and Health in Postmenopausal Phytoestrogen Users clinical trial. Subjects typically recieve the finest healthcare available for their CVD Risk and Health in Postmenopausal Phytoestrogen Users condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > CVD Risk and Health in Postmenopausal Phytoestrogen Users  CVD Risk and Health in Postmenopausal Phytoestrogen Users
CVD Risk and Health in Postmenopausal Phytoestrogen Users
For Condition: Bone Diseases,Cardiovascular Diseases,Coronary Disease,Depression,Heart Diseases,Myocardial Ischemia,Osteoporosis,Postmenopause
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine the acceptability and benefits of use of a dietary supplement of the phytoestrogen, genistein, versus placebo on heart disease risk factors, bone density, and psychosocial outcomes in postmenopausal women.
Details: BACKGROUND: Estrogen replacement therapy is beneficial for heart disease risk factors as well as for bone density. However, a large proportion of postmenopausal women are not compliant with therapeutic regimens. Phytoestrogens are naturally occurring compounds found in plants and soy products that have estrogenic effects, and may represent an alternative treatment for the prevention of heart disease and osteoporosis in postmenopausal women. However, few intervention trials have examined the extent to which it is possible to improve heart disease risk factors, bone density, and quality of life in postmenopausal women through use of a dietary supplement of phytoestrogen. DESIGN NARRATIVE: Randomized, double-blind, placebo-controlled study. A total of 210 women were enrolled in the study to be followed for one to two years. The women were randomized to phytoestrogen treatment or to placebo. Data are collected at baseline visits, at one and three month follow-up telephone calls, and at 6, 12, and 24 month follow-up clinic visits. Measures of high density lipoprotein and other heart disease risk factors, hip and spine bone density, and depression, life satisfaction, and quality of well-being are obtained. Cross-sectional and longitudinal comparisons of treatment and placebo goups are performed before and after adjustment and stratification for potentially confounding covariates. The study was renewed in March 2002 to assess whether the women treated with phytoestrogens had lowered homocysteine, interleukin-6, C-reactive protein, E-selectin, and decreased obesity and fat mass over two years.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 45 Years/74 Years
Genders: Female
Protocol Entry Criteria: Postmenopausal women, ages 45 to 74.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DonnaKritz-Silverstein, , University of California at San Diego
Additional Information:
Study ID Numbers: 116;
Study Start Date: April 1997
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000613
Other Coronary Disease Studies:
1. Coronary Heart Disease Risk Factors in Blacks Vs Whites
2. Multicenter Unsustained Tachycardia Trial (MUSTT)
3. Coronary Artery Surgery Study (CASS)
4. Lipoprotein Subfractions and Coronary Heart Disease During 25 Year Follow-up
5. Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease
Related Studies:
Other Coronary Disease Clinical Trials
Other Clinical Trials
Other Clinical Trials
CVD Risk and Health in Postmenopausal Phytoestrogen Users
|
|
|
|
|
|
|
|
